This Hers review covers the women’s telehealth brand of NYSE-listed Hims & Hers Health — and the most dramatic reinvention in our 2026 rankings. After regulators cracked down on its compounded semaglutide marketing in 2025, Hers rebuilt its weight loss program around FDA-approved, brand-name medication: Wegovy pens from $199/month, Zepbound from $299/month, and oral GLP-1 pills from $149/month. It scores 8.5/10 on this site.
The trade-off is a two-part bill. A required membership costs $39 the first month, then $149/month — and Hers itself says that fee does not include or guarantee a prescription. Below we break down the real monthly cost, the September 2025 FDA warning letter, and the February 2026 Novo Nordisk lawsuit, so you know exactly what you are signing up for.
What Is Hers?
Hers is the women’s brand of Hims & Hers Health, Inc., the publicly traded telehealth company listed on the New York Stock Exchange under ticker HIMS. The platform has operated since 2017 and is licensed in all 50 states, including Alaska and Hawaii. It is LegitScript certified and holds a BBB A+ rating.
As of mid-2026, the Hers weight loss program runs on a two-part model: a Weight Loss Membership billed monthly, plus medication billed separately on top. The menu is now built around brand-name GLP-1s — the Wegovy pen and Wegovy pill, Ozempic injection and Ozempic pill, the Foundayo pill, and Zepbound in vial and KwikPen formats — plus generic liraglutide at $615/month, per Healthline’s March 2026 reporting.
That brand-name focus is recent, and the backstory matters. Hers built much of its weight loss business on compounded semaglutide, which is not FDA-approved. On September 9, 2025, the FDA sent Hims & Hers Health, Inc. dba Hers a warning letter (no. 716825) over false or misleading marketing of that compounded semaglutide, citing sections 502(a) and 502(bb) of the FD&C Act. A parallel letter went to the Hims brand, HIMS stock fell about 8% on the news, and the letters were part of a wave of 55+ FDA warning letters to compounded GLP-1 sellers announced on September 16, 2025.
Hers responded by pivoting. By March 2026 it said it had shifted focus to FDA-approved treatments, limiting compounded semaglutide to cases of medical necessity, and by July 2026 its old prepaid compounded plans had been replaced by the membership-plus-medication model, per third-party reviews. Then came a second blow: Novo Nordisk sued Hims & Hers on February 9, 2026, alleging its compounded semaglutide products infringed U.S. Patent 8,129,343.
Hers Pricing in 2026
Hers splits your bill in two: the membership and the medication. These are the prices listed on the official Hers drug-pricing page, verified in July 2026.
| Item | Price (July 2026) |
|---|---|
| Weight Loss Membership (required) | $39 first month, then $149/mo |
| Wegovy pill, Ozempic pill, Foundayo pill | From $149/mo |
| Wegovy pen, Ozempic injection | From $199/mo |
| Zepbound vial, Zepbound KwikPen | From $299/mo |
| Mounjaro / Zepbound retail pens | $1,899/mo |
| Generic liraglutide | $615/mo (per Healthline, March 2026) |
| Shipping | $5 per order (per third-party pricing reports) |
Three fine-print rules change the math. First, every medication number is a from-price. Hers does not publish a full dose-by-dose price table, and third-party reviewers note that medication cost varies by dose — so the $199 Wegovy pen you start on can cost more as you titrate up. That is a real transparency gap; rival Ro publishes its dose-based price ranges.
Second, the membership is mandatory and separate. It auto-renews at $149/month, it bills even in months when you buy no medication, and the official site states plainly that it does not include or guarantee a prescription. Per third-party pricing reports checked July 9, 2026, the cheapest realistic first month — pill, membership, and $5 shipping — totals about $193, and ongoing months run about $303.
Third, refunds are narrow. Initial medication orders can be refunded only if canceled within 48 hours; shipped orders are non-refundable; and canceling your medication does not cancel the membership. Hers does not accept insurance — everything is cash pay — and HSA/FSA eligibility is reported inconsistently by third parties, so confirm before you count on it.
One legacy note: Hers used to sell compounded semaglutide from $199/month on a 6-month prepaid plan ($1,194 upfront) and oral medication kits (metformin, bupropion, and naltrexone combinations) from $69/month. The prepaid compounded plans are discontinued, and the kits no longer appear on the official drug-pricing page, though one third-party review still lists them.
How Hers Works
The Hers process is one of the simplest we have documented, and it runs the same way in most states.
Step 1: Sign up and intake. You create a profile on the website or app — a government ID is required — and complete a medical intake questionnaire covering your weight history, medications, and health conditions.
Step 2: Provider review. A licensed provider reviews your intake asynchronously, typically within 24 hours, over secure messaging. No video visit is required in most states, and no lab work is required — a genuinely lower barrier than many competitors set.
Step 3: Prescription and delivery. If treatment is clinically appropriate, the provider prescribes and your medication ships to your home with $5 standard shipping. A prescription is never guaranteed — Hers says so itself, and that honesty is a point in its favor.
Step 4: Ongoing care. The membership includes ongoing provider messaging and check-ins for dose titration, plus app-based coaching tools.
Hers Review: What Results Can You Expect?
No honest Hers review can promise a number — results come from the medication, not the platform that ships it. In clinical trials, weekly semaglutide 2.4 mg (the Wegovy dose) produced an average 14.9% body-weight loss over 68 weeks in the STEP 1 trial, and tirzepatide (Zepbound’s molecule) reached up to 20.9% over 72 weeks at the highest dose in SURMOUNT-1. Both trials paired medication with diet and exercise changes, and individual results vary widely.
Expect a slow build either way. The FDA’s Wegovy label titrates patients from 0.25 mg up to the 2.4 mg maintenance dose over roughly four months — and because Hers uses from-pricing, your bill may climb during that ramp.
On service quality, Hers averages about 3.8/5 across roughly 7,000 customer reviews, per Healthline’s March 2026 reporting — one of the stronger reputations among the 11 providers we cover. The recurring complaints are specific, though: inconsistent shipping, slow customer service, and difficulty canceling subscriptions. That last one matters, because canceling your medication does not cancel the $149/month membership.
Hers vs Ro
Ro (8.8/10) is the closest rival to Hers: both sell brand-name GLP-1s with an identical $39-then-$149/month membership stacked on top. Here is the side-by-side.
| Feature | Hers | Ro |
|---|---|---|
| Our score | 8.5/10 (Very Good) | 8.8/10 (Very Good) |
| Membership | $39 first month, then $149/mo | $39 first month, then $149/mo |
| Oral GLP-1s | Pills from $149/mo | Pills $149 first month, then $199–$299/mo |
| Wegovy pen | From $199/mo | $199 first month, then $199–$399/mo |
| Dose-by-dose price table | Not published | Published dose ranges |
| Insurance support | Not accepted — cash only | Free check + prior-authorization concierge |
| BBB record | A+ | B rating, 610 complaints |
| Customer reviews | ~3.8/5 across ~7,000 reviews | ~3.7/5 on Trustpilot (2,300+) |
| Regulatory record | FDA warning letter Sept 2025; Novo Nordisk suit Feb 2026 | None found in our research |
Ro wins on insurance and transparency: its concierge files the prior-authorization paperwork that can cut medication cost to a copay, and it publishes the dose-based price ranges that Hers keeps vague. Hers counters with a cleaner BBB file, a slightly stronger customer-review average, and a women-focused experience — but its September 2025 warning letter and the pending Novo Nordisk lawsuit are blemishes Ro simply does not have. Our full Ro review covers that side of the ledger.
If pills are the deciding factor, both platforms now sell them from $149 the first month — our comparison of oral GLP-1 options ranks every needle-free program on price and fine print.
Who Should Use Hers — and Who Shouldn’t
Use Hers if you want a women-focused, brand-name program. The intake, content, and care flow are designed for women, and every headline medication is FDA-approved. Our roundup of GLP-1 programs for women compares Hers against every other option in this niche.
Use Hers if you hate needles. Oral GLP-1s from $149/month — the Wegovy pill, Ozempic pill, and Foundayo pill — give Hers one of the strongest pill menus sold online today.
Use Hers if you want the lowest-friction signup. Asynchronous provider review typically within 24 hours, no video visit in most states, and no lab work required.
Skip Hers if you have insurance that might cover GLP-1s. Hers takes no insurance at all. Ro’s free coverage check and prior-authorization concierge can turn a $300+ cash bill into a membership fee plus a copay.
Skip Hers if you are cash-strapped. About $303/month is the realistic floor here. Compounded semaglutide from other telehealth providers runs $99–$299/month with no membership fee — though compounded drugs are not FDA-approved, so you are trading supply-chain certainty for savings.
Skip Hers if you want coaching built in. The membership includes messaging and app tools, but not a structured behavior-change program. Our Noom Med review covers the rival that bundles compounded medication with psychology-based coaching from $129 the first month.
Standard qualification rules apply: telehealth providers generally require a BMI of 30+, or 27+ with a weight-related condition such as high blood pressure or type 2 diabetes. Expect disqualification for a personal or family history of medullary thyroid carcinoma or MEN 2, a history of pancreatitis, or current pregnancy.
Is Hers Legit? Our Verdict
Yes — Hers is legit, and at 8.5/10 (Very Good) it earns the third-highest score on this site. It is operated by a NYSE-listed company that has run telehealth at national scale since 2017, holds a BBB A+ rating and LegitScript certification, serves all 50 states, and now centers its weight loss menu on FDA-approved, brand-name medication at cash prices far below the $1,899/month retail figures listed on its own pricing page.
Legit does not mean spotless, and the record deserves plain language. The FDA formally warned Hers on September 9, 2025 over false or misleading marketing of compounded semaglutide — a drug that is not FDA-approved. Novo Nordisk sued the parent company in February 2026 over those same compounded products. The $149/month membership does not guarantee a prescription, medication prices rise with dose without a published full price table, the refund window closes 48 hours after ordering, and customers report real friction when canceling.
How This Hers Review Scored the Brand
Our score comes from the public 5-factor rubric on our How We Rank page: pricing transparency (30%), total cost (25%), safety and sourcing (20%), service flexibility (15%), and reputation (10%). Hers scores high on safety and sourcing after its brand-name pivot, and on flexibility — all 50 states, asynchronous visits, pills and pens alike. It loses points on pricing transparency (from-only pricing with no dose table) and carries its regulatory history in the reputation score. These are editorial ratings built from documented research — the official Hers pricing page, BBB records, FDA announcements, and third-party pricing reports verified in July 2026 — not first-hand drug testing, and not paid placement. For a woman who wants brand-name Hers weight loss treatment and can budget about $303/month, this is one of the two programs we would shortlist. The other is Ro.